Disc Medicine develops investigational treatments for serious hematologic diseases by targeting red blood cell biology, including heme biosynthesis and iron homeostasis. News about IRON centers on its clinical-stage pipeline, including bitopertin for erythropoietic protoporphyria, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders.
Recurring updates include clinical trial progress, medical-meeting presentations, FDA communications, quarterly financial results, business updates, investor-conference participation, and leadership or organizational changes tied to the company’s development and commercialization planning.
Disc Medicine, Inc. (NASDAQ: IRON) announced a securities purchase agreement yielding $62.5 million in gross proceeds from a registered direct offering. The financing was led by Bain Capital Life Sciences, contributing $50 million, alongside existing investors Access Biotechnology and OrbiMed. The offering includes 1,488,166 shares at $23.00 per share and pre-funded warrants for 1,229,224 shares at $22.9999. The investment will primarily support Disc’s clinical pipeline, which includes three investigational therapies targeting severe hematologic diseases, expected to yield critical clinical trial data mid-2023.
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that CEO John Quisel will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 8:40 a.m. ET. The event will be held virtually, and a live webcast can be accessed via the investor relations section of the company's website. Disc Medicine focuses on developing novel treatments for serious hematologic diseases, targeting key biological pathways, including heme biosynthesis and iron homeostasis. For further details, visit the company's website.
Disc Medicine has secured exclusive rights to MWTX-003, an anti-TMPRSS6 antibody, following an agreement with Mabwell Therapeutics. This drug, which shows promise in treating beta-thalassemia and polycythemia vera, has received FDA acceptance for its Investigational New Drug (IND) application. A phase 1 study is set to commence in the second half of 2023. The agreement includes a $10 million upfront payment, with potential total payments reaching $412.5 million, plus royalties on sales. Disc's focus is on developing treatments for serious hematologic diseases through innovation in iron homeostasis.
Disc Medicine has successfully merged with Gemini Therapeutics, finalized on December 29, 2022, enabling the combined entity to trade under the ticker symbol IRON on Nasdaq. With approximately $175 million in cash and equivalents following a $53.5 million financing round, Disc aims to advance its hematology programs and enhance its clinical pipeline through key trials including bitopertin and DISC-0974. The merger positions Disc for significant growth in addressing hematologic diseases while ensuring operational viability into 2025.